Press Release Jan 29 2026
Filed with NSE · · 28 pages · English
Summary by 6ix AI
The report indicates that revenue growth was impacted by inventory destocking and slower order inflows due to market uncertainties and regulatory delays. Despite these challenges, the company is seeing early signs of recovery in order inflows and has made significant investments to expand its facilities. The filing also discusses the acquisition of Kenalog, which is expected to enhance the company's product portfolio and profitability.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Piramal Pharma
- Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
- Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
- Press Release Nov 05 2025
Later from Piramal Pharma
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
- Press Release Feb 05 2026
- Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
Follow Piramal Pharma into a list and get an email when it puts out news.
Follow Piramal Pharma